Cosciens Biopharma (CSCI) Q2 2024 earnings summary

Executive summary

• Completed post-merger integration work, focusing on identifying synergies and cost reduction opportunities to prioritize growth-driving programs and products.

• Awaiting top-line data in Q3 2024 from the pivotal DETECT trial evaluating macimorelin for childhood-onset growth hormone deficiency.

Financial highlights

• Ended Q2 2024 with $27.8 million in cash and cash equivalents.

• Q2 2024 net loss was $1.4 million ($0.64 per share), compared to $0.9 million ($0.47 per share) in Q2 2023.

• Q2 2024 revenue was $2.3 million, up from $1.4 million in Q2 2023, driven by higher sales of Avenanthramides, Oat Beta Glucan, and Oat Oil.

• Six-month 2024 net loss was $2.8 million ($1.39 per share), compared to $1.1 million ($0.62 per share) in the same period of 2023.

• Six-month 2024 revenue was $4.4 million, up from $4.0 million year-over-year.

Outlook and guidance

• On track to announce top-line data from the DETECT trial in Q3 2024.

• Management expects to provide a comprehensive update on integration and cost-saving initiatives soon.